Elutia, Inc. - Class A (ELUT) earnings

ELUT earnings moved a median of +1.47% by the close. Quarterly and annual ELUT reports and results, each read against the price at its own news timestamp. Back to the ELUT overview →

28 measured ELUT earnings events.

Where these ELUT earnings landedvs 27 measured ELUT earnings reactions
ELUT earningsMiddle 50% · -1.98% to +5.74%Zero: 0.00%Median: +1.47%Median +1.47%-8.00%0+8.00%
Middle 50% of ELUT earnings reactions-1.98% to +5.74%
Median reaction (to close)+1.47%
Measured reactions27
Point-in-time · zero look-ahead

Half of the 27 ELUT earnings events with a measured close landed between -1.98% and +5.74%; 63% closed up.

DateHeadlineEvent5-minTo close
Form 10-Q ELUTIA INC. For: Jun 30SEC filing · Form 10-Q+0.00%+2.73%
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 ResultsPress release-2.16%+6.94%
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026Press release+0.00%-3.73%
Form 10-Q ELUTIA INC. For: Mar 31SEC filing · Form 10-Q+0.00%+4.76%
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery MarketPress release-0.90%+3.00%
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026Press release+0.00%+1.00%
Form 10-K ELUTIA INC. For: Dec 31SEC filing · Form 10-K-1.80%-3.60%
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026Press release+0.00%+6.48%
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x MilestonesPress release+0.00%-8.19%
Form 10-Q ELUTIA INC. For: Sep 30SEC filing · Form 10-Q-0.47%—
Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x DevelopmentPress release-2.17%-2.71%
Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025Press release+2.59%+1.47%
Form 10-Q ELUTIA INC. For: Jun 30SEC filing · Form 10-Q-0.01%+1.00%
Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025Press release—+6.81%
Form 10-Q ELUTIA INC. For: Mar 31SEC filing · Form 10-Q-0.28%-4.97%
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ SalesPress release+0.00%+3.48%
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025Press release+0.00%-5.56%
Form 10-K ELUTIA INC. For: Dec 31SEC filing · Form 10-K—+7.61%
Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025Press release+0.00%+0.00%
Form 10-Q ELUTIA INC. For: Sep 30SEC filing · Form 10-Q+0.00%+0.00%
Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024Press release+0.00%-1.25%
Form 10-Q ELUTIA INC. For: Jun 30SEC filing · Form 10-Q—+6.09%
Elutia Announces Second Quarter 2024 ResultsPress release-5.47%+19.92%
Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024Press release+0.00%-2.93%
Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA ClearancePress release+0.00%+19.20%
Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024Press release—+5.40%
Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial ResultsPress release+0.00%+2.52%
Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023Press release+0.00%+1.40%
That’s how ELUT usually reacts to earnings — get an email when it moves on news →
Keep exploring

More ELUT: analyst actions → · SEC filings → · ELUT overview →